

**Change Memo for**  
**“The National Healthcare Safety Network (NHSN)”**  
**(OMB Control No. 0920-0666)**  
**Expiration Date: 12/31/2022**

**Program Contact**

Lauren Wattenmaker  
Surveillance Branch  
Division of Healthcare Quality Promotion  
National Center for Emerging and Zoonotic Infectious Diseases  
Centers for Disease Control and Prevention  
Atlanta, Georgia 30333  
Phone: 404-718-5842  
Email: nlh3@cdc.gov

-

**Submission Date:** June 2, 2020

The Centers for Disease Control and Prevention (CDC), Division of Healthcare Quality Promotion (DHQP) requests a nonmaterial/non-substantive of the currently approved Information Collection Request: “National Healthcare Safety Network (NHSN) (OMB Control No. 0920-0666).”

The CDC seeks to update eight data collection instruments from the NHSN Patient Safety Component. Seven forms will be updated to include an optional field for the facility to indicate whether the patient has suspected or confirmed COVID-19. NHSN is adding this field to help CDC determine potential association of healthcare-associated infections (HAIs) with COVID-19 and patient outcomes. Many facilities are currently reporting this information as a comment and/or in a custom field for their own facility use. Adding fields that specifically request information about COVID-19 presence will enable consistent data analysis in NHSN for facilities and for CDC’s use. Because facilities are already collecting information on COVID-19, we estimate the burden to be nominal and have therefore added one additional minute to each form.

The additional form CDC seeks to update allows CDC to capture use of the antiviral agent Remdesivir. Adding this drug will allow CDC to monitor and track use related to the COVID-19 pandemic. Data collected on form 57.124 are submitted via electronic data submission only. Adding this drug requires an update to vendor software but no additional burden for facilities submitting the data.

<b>Type of Respondent</b>	<b>Form Name</b>	<b>No. of Respondents</b>	<b>No. Responses per Respondent</b>	<b>Avg. Burden per response (in hrs.)</b>	<b>Total Burden (in hrs.)</b>	<b>Change in Burden (in hrs.)</b>
Microbiologist (IP)	57.108 Primary Bloodstream Infection	5,775	5	39/60	18,769	18,288
Microbiologist (IP)	57.111 Pneumonia (PNEU)	1,800	30	31/60	27,900	27,000
Microbiologist (IP)	57.112 Ventilator Associated Event	5,500	5	29/60	13,292	12,833
Microbiologist (IP)	57.113 Pediatric Ventilator Associated Event	334	120	31/60	20,708	20,040
Microbiologist (IP)	57.114 Urinary Tract Infection	5,500	5	21/60	9,625	9,167
Microbiologist (IP)	57.115 Custom Event	600	91	36/60	32,760	31,850
Microbiologist (IP)	57.120 Surgical Site Infection	4,500	11	36/60	29,700	28,875
Pharmacist	57.124 Antimicrobial Use and	2,000	12	5/60	2,000	0

	Resistance (AUR)-Pharmacy Data Electronic Upload Specification Tables					
--	--	--	--	--	--	--

The overall burden for this package approved on December 2, 2020 was 3,113,631 hours. These changes represent an overall burden increase of 4,701 hours for a new total of 3,118,332 hours for the package.